• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在使用纳武单抗（抗PD-1抗体）治疗转移性皮肤恶性黑色素瘤过程中出现类似伏格特-小柳-原田病的后葡萄膜炎，期间使用了维莫非尼（BRAF抑制剂）。

Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.

作者信息

Matsuo Toshihiko, Yamasaki Osamu

机构信息

Department of Ophthalmology Okayama University Hospital and Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama City Japan.

Department of Dermatology Okayama University Hospital and Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama City Japan.

出版信息

Clin Case Rep. 2017 Mar 31;5(5):694-700. doi: 10.1002/ccr3.911. eCollection 2017 May.

DOI:10.1002/ccr3.911
PMID:28469878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5412830/
Abstract

A patient with metastatic cutaneous malignant melanoma developed Vogt-Koyanagi-Harada disease-like posterior uveitis after two nivolumab (anti-PD-1 antibody) injections. Vogt-Koyanagi-Harada disease, with the background of autoimmunity against choroidal melanocytes, suggests nivolumab be working by disintegrating inhibition circuit of T cells against a common epitope shared between melanoma cells and normal melanocytes.

摘要

一名转移性皮肤恶性黑色素瘤患者在注射两次纳武单抗（抗程序性死亡蛋白1抗体）后发生了类葡萄膜炎-小柳-原田病样后葡萄膜炎。葡萄膜炎-小柳-原田病以针对脉络膜黑素细胞的自身免疫为背景，提示纳武单抗可能是通过破坏T细胞针对黑色素瘤细胞和正常黑素细胞共有的共同表位的抑制回路而发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e7/5412830/bffa9a61fced/CCR3-5-694-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e7/5412830/3dc786033a3e/CCR3-5-694-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e7/5412830/526ffad24b49/CCR3-5-694-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e7/5412830/bffa9a61fced/CCR3-5-694-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e7/5412830/3dc786033a3e/CCR3-5-694-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e7/5412830/526ffad24b49/CCR3-5-694-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e7/5412830/bffa9a61fced/CCR3-5-694-g003.jpg

相似文献

1
Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.在使用纳武单抗（抗PD-1抗体）治疗转移性皮肤恶性黑色素瘤过程中出现类似伏格特-小柳-原田病的后葡萄膜炎，期间使用了维莫非尼（BRAF抑制剂）。
Clin Case Rep. 2017 Mar 31;5(5):694-700. doi: 10.1002/ccr3.911. eCollection 2017 May.
2
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma.纳武单抗（抗PD-1抗体）治疗转移性皮肤恶性黑色素瘤期间出现的类伏格特-小柳-原田病葡萄膜炎
Case Rep Ophthalmol. 2019 Feb 8;10(1):67-74. doi: 10.1159/000496682. eCollection 2019 Jan-Apr.
3
Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.接受派姆单抗治疗后出现 Vogt-Koyanagi-Harada 样葡萄膜炎的转移性皮肤恶性黑色素瘤病例。
Doc Ophthalmol. 2021 Jun;142(3):353-360. doi: 10.1007/s10633-020-09800-0. Epub 2021 Jan 4.
4
Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.维莫非尼诱发的转移性皮肤恶性黑色素瘤所致的类伏格特-小柳-原田病葡萄膜炎
J Dermatol. 2018 Jun;45(6):e159-e160. doi: 10.1111/1346-8138.14200. Epub 2018 Jan 3.
5
VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.序贯纳武利尤单抗和达拉非尼/曲美替尼治疗晚期黑色素瘤患者出现 VOGT-KOYANAGI-HARADA 病样葡萄膜炎。
Retin Cases Brief Rep. 2023 Sep 1;17(5):611-615. doi: 10.1097/ICB.0000000000001251.
6
Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.纳武单抗用于治疗卵巢癌后出现的伏格特-小柳-原田综合征样葡萄膜炎。
Doc Ophthalmol. 2022 Apr;144(2):153-162. doi: 10.1007/s10633-021-09862-8. Epub 2022 Jan 8.
7
VOGT-KOYANAGI-HARADA-LIKE UVEITIS FOLLOWED BY MELANOMA-ASSOCIATED RETINOPATHY WITH FOCAL CHORIORETINAL ATROPHY AND CHOROIDAL NEOVASCULARIZATION IN A PATIENT WITH METASTATIC CUTANEOUS MELANOMA.转移性皮肤黑色素瘤患者出现 VOGT-KOYANAGI-HARADA-LIKE 葡萄膜炎继以伴局灶性脉络膜视网膜萎缩和脉络膜新生血管的黑色素瘤相关视网膜病变。
Retin Cases Brief Rep. 2023 Jan 1;17(1):18-22. doi: 10.1097/ICB.0000000000001113. Epub 2020 Dec 21.
8
A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy.一例由纳武利尤单抗和伊匹木单抗联合治疗诱发的类伏格特-小柳-原田病葡萄膜炎病例
Case Rep Ophthalmol. 2021 Dec 2;12(3):952-960. doi: 10.1159/000520416. eCollection 2021 Sep-Dec.
9
Vogt-Koyanagi-Harada syndrome--isolation of cloned T cells with specificity for melanocytes and melanoma cells.伏格特-小柳-原田综合征——分离出对黑素细胞和黑色素瘤细胞具有特异性的克隆T细胞。
Aust N Z J Ophthalmol. 1989 Nov;17(4):347-52. doi: 10.1111/j.1442-9071.1989.tb00552.x.
10
[Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].免疫检查点抑制剂治疗转移性恶性黑色素瘤时出现的类伏格特-小柳-原田葡萄膜炎
Ophthalmologe. 2020 May;117(5):467-471. doi: 10.1007/s00347-019-00963-z.

引用本文的文献

1
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.晚期肺癌患者使用免疫检查点抑制剂的再激发治疗。
Nat Rev Clin Oncol. 2025 Jun 9. doi: 10.1038/s41571-025-01029-7.
2
Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review.免疫检查点抑制剂相关的类葡萄膜炎-小柳原田综合征：一项描述性系统评价。
J Ophthalmic Inflamm Infect. 2025 May 12;15(1):44. doi: 10.1186/s12348-025-00484-8.
3
Presumed Autoimmune Keratitis in Both Eyes Without Systemic Manifestations: A 40-Year Course of a Patient With Corneal Infiltrates and Melt.

本文引用的文献

1
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.癌症患者免疫检查点阻断相关不良事件：病例报告的系统评价
PLoS One. 2016 Jul 29;11(7):e0160221. doi: 10.1371/journal.pone.0160221. eCollection 2016.
2
Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment.自身免疫性关节病和葡萄膜炎作为程序性死亡1抑制剂治疗的并发症
Arthritis Rheumatol. 2016 Feb;68(2):556-7. doi: 10.1002/art.39406.
3
PD-1/PD-L1 inhibitors.程序性死亡受体1/程序性死亡配体1抑制剂
双眼疑似自身免疫性角膜炎且无全身表现：一名角膜浸润和溶解患者的40年病程
Cureus. 2025 Feb 28;17(2):e79852. doi: 10.7759/cureus.79852. eCollection 2025 Feb.
4
Local Control of Conjunctival Malignant Melanoma by Proton Beam Therapy in a Patient With No Metastasis in Six Years From to Nodular Lesions.质子束治疗对一名无转移的结膜恶性黑色素瘤患者的局部控制：六年随访至结节性病变
J Med Cases. 2025 Jan;16(1):28-36. doi: 10.14740/jmc4351. Epub 2024 Dec 1.
5
Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature.帕博利珠单抗继发于转移性胃癌的类伏格特-小柳-原田葡萄膜炎：一例报告及文献复习
Case Rep Oncol. 2024 Sep 25;17(1):1071-1086. doi: 10.1159/000541133. eCollection 2024 Jan-Dec.
6
Vogt-Koyanagi-Harada disease in pregnancy: Case report and review of 32 patients in the literature.妊娠合并Vogt-小柳-原田病：病例报告及文献中32例患者的回顾
Clin Case Rep. 2024 Mar 11;12(3):e8643. doi: 10.1002/ccr3.8643. eCollection 2024 Mar.
7
Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.诊断与管理免疫检查点抑制剂相关葡萄膜炎：综述
Diagnostics (Basel). 2024 Feb 4;14(3):336. doi: 10.3390/diagnostics14030336.
8
Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.免疫检查点抑制剂药物与葡萄膜炎的关联：利用 TriNetX 数据库进行的基于人群的队列研究。
Front Immunol. 2024 Jan 9;14:1302293. doi: 10.3389/fimmu.2023.1302293. eCollection 2023.
9
Tuberculosis reactivation demonstrated by choroiditis and inflammatory choroidal neovascular membrane in a patient treated with immune checkpoint inhibitors for malignant mucosal melanoma.一名接受免疫检查点抑制剂治疗恶性黏膜黑色素瘤的患者，出现脉络膜炎和炎性脉络膜新生血管膜，提示结核病复发。
J Ophthalmic Inflamm Infect. 2023 Dec 18;13(1):54. doi: 10.1186/s12348-023-00374-x.
10
Unilateral Posterior Uveitis in a Patient Receiving Nivolumab for Malignant Melanoma.一名接受纳武单抗治疗恶性黑色素瘤的患者发生单侧后葡萄膜炎。
Cureus. 2023 Aug 10;15(8):e43311. doi: 10.7759/cureus.43311. eCollection 2023 Aug.
Curr Opin Pharmacol. 2015 Aug;23:32-8. doi: 10.1016/j.coph.2015.05.011. Epub 2015 Jun 2.
4
Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.使用伊匹单抗抑制CTLA-4治疗转移性黑色素瘤后出现的类伏格特-小柳-原田综合征
J Immunother. 2015 Feb-Mar;38(2):80-4. doi: 10.1097/CJI.0000000000000066.
5
Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.维莫非尼治疗晚期皮肤黑色素瘤患者的葡萄膜炎。
JAMA Ophthalmol. 2014 Dec;132(12):1421-5. doi: 10.1001/jamaophthalmol.2014.3024.
6
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.美国食品和药物管理局批准摘要：威罗菲尼用于治疗携带 BRAFV600E 突变的不可切除或转移性黑色素瘤。
Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5.
7
Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.使用维莫非尼治疗的BRAF突变型皮肤黑色素瘤患者的眼部毒性。
Am J Ophthalmol. 2014 Oct;158(4):831-837.e2. doi: 10.1016/j.ajo.2014.07.003. Epub 2014 Jul 15.
8
Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma.一名接受维莫非尼BRAF抑制剂治疗的IV期黑色素瘤患者发生双侧全葡萄膜炎。
Eur J Ophthalmol. 2014 Jul-Aug;24(4):629-32. doi: 10.5301/ejo.5000423. Epub 2014 Jan 22.
9
Diagnosis and classification of Vogt-Koyanagi-Harada disease.Vogt-小柳原田病的诊断和分类。
Autoimmun Rev. 2014 Apr-May;13(4-5):550-5. doi: 10.1016/j.autrev.2014.01.023. Epub 2014 Jan 15.
10
Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.患者在接受维莫非尼治疗转移性黑色素瘤时出现严重的全葡萄膜炎。
BMC Cancer. 2013 Dec 1;13:561. doi: 10.1186/1471-2407-13-561.